A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors Wi
This study is conducted to determine the safety and tolerability of INCB161734 as a single agent or in combination with other anticancer therapies.
| Condition(s) | Solid Tumors |
|---|---|
| Status | Recruiting |
| Phase | Phase 1 |
| Study type | Interventional |
| Summary | This study is conducted to determine the safety and tolerability of INCB161734 as a single agent or in combination with other anticancer therapies. |
| Who can participate | Inclusion Criteria: * ≥18 years old. * Locally advanced or metastatic solid tumor with KRAS G12D mutation. * For Part 1a and Part 2 Combination Groups 1, 2, and 7: Disease progression on prior standard treatment, intolerance to or ineligibility for standard treatment, declined available therapies that are known to confer clinical benefit, or no standard available treatment to improve the disease outcome. * Cohort specific requirements aas defined in the protocol. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Exclusion Criteria: * Prior treatment with any KRAS G12D inhibitor * Known additional invasive malignancy within 1 year of the first dose of study drug * History of organ transplant, including allogeneic stem cell transplantation * Significant, uncontrolled |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Incyte Corporation |
| Locations | Phoenix, Arizona, United States; Palo Alto, California, United States; Santa Monica, California, United States; Denver, Colorado, United States; Jacksonville, Florida, United States; Sarasota, Florida, United States (+31 more sites) |
| Start date | 2024-01-04 |
| NCT ID | NCT06179160 |
| Official listing | https://clinicaltrials.gov/study/NCT06179160 |